Global Health Share Price Today (MEDANTA)
TODAY IN ONE LINE
MEDANTA slipped 0.5% on light volume, in line with Nifty's 0.3% move, supported by recent strong earnings.
With a market cap of ₹35,751.81 Cr., it trades at a P/E of 63.90. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Global Health flags
Key strengths and potential risks.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 42.0% YoY
- ●High Capital EfficiencyROCE of 17.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.2%
- ●Healthy Operating MarginsOPM is structurally strong at 20.8%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 64.5x
- ●Rising Receivables vs SalesReceivables grew 31.3% outpacing sales growth of 12.7%
What changed recently?
Recent events, corporate actions, and announcements.
Global Health Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Global Health Limited, framed against the sector median so the premium or discount is obvious at a glance.
Global Health Limited trades at a P/E of 63.90× and P/B of 8.97×, against the Healthcare sector median P/E of 44.84×.
Valuation
Profitability
Growth
Financial Health
Global Health Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Global Health Limited — derived from the live tape, not yesterday's close.
Global Health Limited last traded at ₹1,332.3 with an intraday range of ₹1,327–₹1,343 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1332.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1373.20 | +40.90 | +3.07% |
| R3 | 1357.20 | +24.90 | +1.87% |
| R2 | 1350.10 | +17.80 | +1.34% |
| R1 | 1341.20 | +8.90 | +0.67% |
| PIVOT | 1334.10 | 1.80 | 0.14% |
| CURRENT | 1332.30 | — | — |
| S1 | 1325.20 | -7.10 | -0.53% |
| S2 | 1318.10 | -14.20 | -1.07% |
| S3 | 1309.20 | -23.10 | -1.73% |
| S4 | 1293.20 | -39.10 | -2.93% |
MEDANTA is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1330.6–₹1343
Trading Inside opening range
Global Health Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Global Health Limited, switchable between annual and quarterly views, consolidated or standalone.
Global Health Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹35,751.81 Cr. and reported EPS of ₹20.62.
| Period | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue from Operations | 2,694 | 3,275 | 3,692 | 4,410 |
| Other Income | 65 | 75 | 79 | 99 |
| Total Income | 2,759 | 3,350 | 3,771 | 4,509 |
| Cost of Goods Sold (COGS) | 625 | 759 | 880 | 997 |
| Gross Profit | 2,069 | 2,516 | 2,813 | 3,413 |
| +Operating Expenses | 1,457 | 1,717 | 1,936 | 2,494 |
| EBITDA | 612 | 799 | 877 | 919 |
| +Non-Operating Expenses | 228 | 247 | 209 | 301 |
| Profit Before Tax (PBT) | 449 | 627 | 647 | 715 |
| +Tax Expense | 123 | 149 | 166 | 161 |
| Total Profit for Period | 326 | 478 | 481 | 554 |
| Less: Non-controlling Interests | — | -0 | -0 | -2 |
| Net Profit (Owner's PAT) | 326 | 478 | 481 | 556 |
| Earnings Per Share (EPS) | 12.16 | 17.81 | 17.92 | 20.70 |
| Diluted Shares Outstanding (Nos.) | 27 | 27 | 27 | 27 |
| +Additional Disclosures | 2,937 | 3,481 | 4,003 | 4,792 |
| Sales Growth % | — | 21.56 | 12.74 | 19.44 |
| YoY Sales Growth % | — | 21.56 | 12.74 | 19.44 |
| Material Cost % | 21 | 21 | 21 | 20 |
| Employee Cost % | 24 | 22 | 22 | 25 |
| Other Cost % | 31 | 30 | 30 | 32 |
| OPM % | 23 | 24 | 24 | 21 |
| Tax % | 27 | 24 | 26 | 23 |
| Profit Growth % | — | 46.65 | 0.68 | 15.58 |
| Gross Margin % | 76.79 | 76.81 | 76.18 | 77.40 |
| EBITDA Margin % | 22.72 | 24.40 | 23.75 | 20.84 |
| Interest Coverage Ratio | 5.93 | 8.47 | 10.47 | 8.80 |
| Ebit | 462 | 626 | 683 | 697 |
Global Health segment analysis: revenue and profit mix.
Disclosed business segments at Global Health with their share of revenue and profit, switchable between consolidated and standalone reporting.
Global Health discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Global Health Limited.
Our AI distills the core fundamental drivers supporting Global Health Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Global Health Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 42% YoY, demonstrating robust earnings momentum and operational leverage.
Operating margin 15.79% TTM and net margin 12.62% TTM exceed peer benchmarks, signaling pricing power.
ROCE 17.10% and ROE 15.20% indicate efficient capital deployment and strong returns on invested capital.
Low debt-to-equity 0.0030x with absolute debt ₹0.01 LCr ensures financial resilience and flexibility.
TTM revenue growth 24.50% YoY outpaces sector peers, reflecting strong market demand and expansion.
Key Risks.
P/E ratio 64.49x signals elevated valuation risk relative to historical and peer averages.
Dividend yield 0.04% and payout ratio 2.42x unsustainable, limiting shareholder returns significantly.
Net cash flow negative ₹94.16 Cr despite positive operating cash flow strains liquidity position.
High capex ₹931.35 Cr exceeds operating cash flow ₹573.32 Cr, pressuring free cash flow generation.
Promoter holding 33.01% below typical comfort levels, raising governance and control concerns.
Flip Conditions.
Trim if P/E re-rates above 83 (~1.9× the sector multiple of 44.8). The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Exit if ROE slips below 10%. The operating engine is no longer compounding capital efficiently.
Income thesis breaks if the dividend is cut or yield falls below 0.02%.
Global Health Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Global Health Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Global Health Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Global Health Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Global Health Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Global Health Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Global Health Limited stood at 60.1% of traded volume, against a 20-day average of 56.6%.
Global Health announcements: results, concalls, ratings, M&A.
Filings Global Health sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Global Health files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 186 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Global Health Limited has informed the Exchange about Certificates under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended…
Trading Window
Global Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
ESOP/ESOS/ESPS
Global Health Limited has informed the Exchange regarding Allotment of 4000 Shares.
Analysts/Institutional Investor Meet/Con. Call Updates
Global Health Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Global Health Limited has informed the Exchange about Schedule of meet.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Global Health dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Global Health has declared, sequenced by announce and record date.
Global Health corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Global Health Limited: business, sector, key facts.
What Global Health Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Global Health Limited operates in the Hospital industry under the Healthcare sector, listed as NSE: MEDANTA, BSE: 543654.
Medanta, operating under Global Health Limited, is a prominent healthcare provider in India offering a comprehensive range of medical services. Their business model centers around a network of hospitals under the Medanta brand, delivering advanced medical treatments across numerous specialties. This wide-ranging approach allows them to cater to a broad spectrum of patient needs, from routine check-ups to complex, life-saving procedures.
The company's services span a vast array of medical disciplines. These include highly specialized areas such as cardiac and cancer care, neurosciences, liver and lung transplants, and bone marrow transplants. Alongside these advanced treatments, Medanta also provides a comprehensive suite of general medical services, encompassing digestive and hepatobiliary sciences, musculoskeletal disorders and orthopedics, renal care, and a wide range of surgical specialities including plastic, aesthetic and reconstructive surgery, ENT, and chest surgery. Furthermore, they offer substantial care for women's health, covering gynecology, obstetrics, and pediatric care.
Beyond direct patient care, Medanta's business extends to supporting services that enhance the patient experience and overall healthcare access. These ancillary services include advanced diagnostic and laboratory testing, convenient homecare and elder care options, and the utilization of telemedicine to expand reach. They also provide critical support services like a blood bank, e-ICU services, and air ambulance services for emergency situations. In addition, Medanta offers health plans to facilitate access to their services and operates in-house pharmacies for patient convenience.
In summary, Medanta's business model integrates advanced medical treatments with comprehensive support services to establish a robust and multifaceted healthcare system. Their focus on a wide range of specializations, coupled with their commitment to ancillary services, positions Medanta as a major player in the Indian healthcare market, providing a holistic approach to patient care and accessibility.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Dr Agarwal's Health Care (AGARWALEYE) Share PricePeer
- Apollo Hospitals Enterprise (APOLLOHOSP) Share PricePeer
- Artemis Medicare Services (ARTEMISMED) Share PricePeer
- Aster DM Healthcare (ASTERDM) Share PricePeer
- Fortis Healthcare (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Global Health Limited (MEDANTA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Global Health Limited (MEDANTA)?
The current share price of Global Health Limited (MEDANTA) is ₹1,332.3. Today, the stock has declined by ₹6.20 (0.46%), trading in a range of ₹1,327 to ₹1,343. The stock opened at ₹1,343 with a trading volume of 13,762 shares.
02Is Global Health Limited stock a good investment for long-term?
Global Health Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹35,751.81 crores, P/E ratio of 63.90, ROE of 15.20%, and ROCE of 17.10%. The dividend yield stands at 0.04%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Global Health Limited stock?
The 52-week high price of Global Health Limited (MEDANTA) is ₹1,456.5, while the 52-week low is ₹956. Currently trading at ₹1,332.3, the stock is 75.2% away from its 52-week low and 8.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Global Health Limited stock at the current price?
Whether to buy Global Health Limited stock at ₹1,332.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 63.90 and P/B ratio of 8.97. Today's performance shows a loss of 0.46%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Global Health Limited and when is the next dividend?
Global Health Limited offers a dividend yield of 0.04%, which means for every ₹100 invested at the current price of ₹1,332.3, you can expect to receive approximately ₹0.04 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Global Health Limited?
Global Health Limited's key financial metrics include: P/E Ratio: 63.90, P/B Ratio: 8.97, ROE: 15.20%, ROCE: 17.10%, Dividend Yield: 0.04%, EPS: ₹20.62, Book Value: ₹147.47, and Debt-to-Equity: 0.00. The company's market cap stands at ₹35,751.81 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Global Health Limited stock performing today in the market?
Global Health Limited stock opened at ₹1,343 and is currently trading at ₹1,332.3, showing a decline of ₹6.20 (0.46%). The intraday high is ₹1,343 and low is ₹1,327. The trading volume stands at 13,762 shares, indicating moderate market participation today.
08What is the P/E ratio of Global Health Limited and what does it indicate?
Global Health Limited has a Price-to-Earnings (P/E) ratio of 63.90, which means investors are willing to pay ₹63.90 for every ₹1 of earnings. With an EPS of ₹20.62, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Global Health Limited (MEDANTA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.